This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the fifth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the third installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with Meg Doherty, MD, MPH, PhD, Director Global HIV, Hepatitis and STI Programmes at WHO, about ...

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by ...

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

Laura Bergner receives funding from the Wellcome Trust (Institutional Strategic Support Fund Early Career Researcher Catalyst Grant) and the Human Frontier Science Program (RGP0013/2018). Daniel ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...